The STAT3 activation confers survival and acquired TKI resistance of CML LSCs in BMM through BCR-ABL1-independent mechanisms, suggesting a different role for STAT3 in drug resistance of CML [123]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.